Straumann Holding AG stock (CH0012280076): Zurich gains bring shares closer to 52-week high

Straumann Holding AG shares advanced on SIX Swiss Exchange trading in Zurich on 06/03/2026, moving closer to their 52-week high as investors continued to focus on the Swiss dental implant group's growth profile and recent financial performance.

Straumann Holding AG shares traded higher on SIX Swiss Exchange in Zurich on 06/03/2026, with the move bringing the stock closer to its 52-week high as investors continued to focus on the Swiss dental implant and orthodontics specialist's growth profile, according to intraday exchange data as of the afternoon session.

The stock traded at CHF 139.40 on 06/03/2026 on SIX Swiss Exchange, up around 1.8% on the day with volume modestly above the recent daily average, according to SIX price data as of early afternoon.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Straumann
• Sector/industry: Dental implants, orthodontics, medical devices
• Headquarters/country: Basel, Switzerland
• Core markets: Europe, North America, Asia-Pacific
• Key revenue drivers: Dental implants, orthodontic clear aligners, digital dentistry solutions
• Home exchange/listing venue: SIX Swiss Exchange (STMN)
• Trading currency: CHF

Straumann Holding AG: core business model

Straumann focuses on premium and value dental implants and orthodontic solutions, with revenues largely generated by selling implant systems, clear aligners and associated digital workflows to dental professionals worldwide.

Straumann Holding AG in peer comparison

Against its main listed peers in the global dental space, Straumann is often viewed as a premium-growth name, and recent trading underscores that positioning. Swiss rival Nobel Biocare was taken private by Danaher several years ago, leaving Straumann as the primary pure-play dental implant group on the Swiss market. In the broader dental sector, U.S.-listed Dentsply Sirona and Envista compete across implants, orthodontics and equipment, but both have more diversified product portfolios beyond implants and aligners.

While Straumann generated CHF 2.3 billion in revenue in 2024 with an operating margin in the mid-20 percent range, Dentsply Sirona reported 2024 revenue in the multi-billion-dollar range with lower margins as it balances a broad equipment and consumables offering. Envista, which has also been reshaping its portfolio, posted 2024 sales around the USD 2.7 billion mark, reflecting a strong presence in implants and orthodontics but still lagging Straumann on profitability metrics. Investors in Zurich have been rewarding Straumann's relatively focused strategy and margin profile, as reflected in its approach toward the 52-week high in recent sessions.

Conclusion

The advance of Straumann Holding AG shares on SIX Swiss Exchange on 06/03/2026 brings the Swiss dental group's stock closer to its 52-week high, underlining continuing investor interest in the name. When seen alongside peers such as Dentsply Sirona and Envista, Straumann's focused implant and aligner footprint and solid profitability help explain why the Zurich listing remains closely watched. How the valuation gap versus other dental stocks evolves will likely depend on the group's ability to sustain growth and margins in upcoming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.